The role of inhaled nitric oxide (INO) 
Congenital diaphragmatic hernia (CDH) occurs in 1 of every 2200 to 4200 births. 1 Neonates with CDH frequently develop hypoxemic respiratory failure requiring aggressive support to maintain gas exchange in hypoplastic lungs that are subject to severe pulmonary hypertension. Initial treatment of hypoxemic respiratory failure in newborns with CDH is generally consistent with management of persistent pulmonary hypertension of the newborn, and includes sedation, permissive hypercapnia, highfrequency oscillatory ventilation, and the avoidance of acidosis and barotrauma. 2, 3 When these modalities fail, neonates with CDH may be supported with extracorporeal membrane oxygenation (ECMO), which has been shown to improve survival. 4, 5 Nitric oxide, an important endogenous mediator of vascular tone, causes vascular smooth muscle relaxation and subsequent vasodilatation. 6, 7 Inhaled nitric oxide (INO) has a prominent role in the treatment of severe hypoxemic respiratory failure from a variety of causes because of its proven efficacy in decreasing ventilation-perfusion mismatch and improving oxygenation. 8, 9 In both primary and secondary persistent pulmonary hypertension of the newborn, INO improves oxygenation, reduces the need for ECMO, or improves neurodevelopmental outcomes when other therapies fail. [10] [11] [12] [13] Clinicians have hoped that pulmonary hypertension in patients with CDH would respond similarly; however, no randomized trial has demonstrated that INO improves outcomes in these patients. Two well-designed, methodologically sound trials found that early INO treatment fails to improve survival or reduce need for ECMO in newborns with CDH. 10, 14 In fact, INO therapy may actually increase the need for ECMO in this population. A Cochrane review concluded that early INO does not improve outcomes in neonates with CDH, may in fact worsen outcomes, and recommends against using INO to manage early hypoxemic respiratory failure in these patients. 11 The purpose of this study was to describe the current utilization, trends, interhospital variability, and costs associated with INO use in a nationally representative cohort of newborns with CDH treated at pediatric referral centers in the United States.
METHODS
Data for this study were obtained from the Pediatric Health Information System (PHIS), an administrative database that contains inpatient, emergency department, ambulatory surgery, and observation data from 43 not-for-profit, tertiary care pediatric hospitals in the United States. These hospitals are affiliated with the Children' s Hospital Association. The data warehouse function for the PHIS database is managed by Truven Health Analytics. Data are de-identified at the time of data submission and are subjected to reliability and validity checks before inclusion in the database.
Hospitals were excluded from the study if they did not submit billing data, or did not have an ECMO program during the study period. SPSS Statistics, IBM Corporation, Armonk, NY). Correlations between 9-year hospitalspecific rates of mortality, CDH surgical repair, INO use, and ECMO use were described by using Spearman' s r (r s ). Relationships between hospital characteristics and proportion of infants with diaphragmatic hernia treated with INO were evaluated by using t tests for continuous variables, and x 2 tests for categorical variables. Univariate and multivariate analyses of nonindependent data were performed with hierarchical linear or logistic regression using HLM version 6.08 (Scientific Software International, Inc., Lincolnwood, IL). 20 Nonindependence occurred as a result of clustering of infants within hospitals when examining infant characteristics associated with INO therapy, or was a result of repeated measures of hospital rates when testing for secular trends in mortality, use of INO, INO charges, or use of ECMO. All statistical tests were 2-tailed with P , .05 considered significant.
RESULTS
A total of 1713 neonates with CDH were identified from 33 PHIS hospitals from 2003 to 2011. We excluded records for patients who were readmitted (n = 6), had congenital cardiac anomalies (n = 2008), were alive and did not undergo CDH repair during the first 60 days of life (n = 220), or had missing or incomplete billing data (n = 108). Most subjects were white boys with a median gestational age of 38 weeks and a median birth weight of 3000 g (Table 1). More than three-quarters were admitted to the PHIS hospital on their first day of life. Median inpatient stay was 25 days (interquartile range [IQR] 14-47) overall, including 32 days (IQR 20-59) for survivors and 15 days (IQR 2-29) for nonsurvivors. Median age for CDH repair was 5 days (IQR 3-10). Overall mortality rate was 34% (n = 578) for the study cohort, ranging from 14% to 65% between hospitals. Mortality rate was 100% among infants not undergoing CDH repair. One-third of nonsurvivors (33%) died during the first 3 days of life.
More than half (57%) of neonates with CDH received INO, with a median course of therapy of 8 days (IQR 2-18). Eleven percent of neonates receiving INO had a course of therapy of 30 days or longer, and 3% received .60 days of treatment. Peak INO use was on the second day of life, with 38% of patients being treated (Fig 1) Wide variation in INO use was seen between PHIS hospitals, ranging from 34% to 92%. Hospital case volume, defined as total CDH cases treated by a hospital during the study period, ranged from 15 to 120 and did not correlate with repair rate (r s = 0.14), INO use (r s = -0.17), ECMO therapy (r s = -0.07), or mortality (r s = -0.03).
Nearly one-quarter (23%) of patients with CDH were treated with ECMO for a total of 4814 days. This included 2414 days of ECMO before surgical repair, and 939 days in infants who died before repair. Peak ECMO use occurred on the seventh and eighth days of life, and 40% of patients were repaired on ECMO. ECMO runs had a median of 11 days (IQR 7-17). Most (80%) infants were treated with INO on the day of ECMO cannulation.
The proportion of patients treated with INO and their duration of treatment increased significantly during the study period (Fig 2) . In multivariate regression analysis, the adjusted baseline percentage of infants receiving INO at studied hospitals was 51.1%, and increased by an average of 1.4% per year during the study period (95% confidence interval [CI] 0.2%-2.7%, P , .05). Odds of receiving INO increased by 6.1% per year for infants at PHIS hospitals during the study period (odds ratio [OR] 1.06, 95% CI 1.01-1.12, P , .05). This included significant increases in use of INO on the day of CDH repair (OR 1.09, 95% CI 1.03-1.15, P , .05) and after repair (OR 1.07, 95% CI 1.01-1.14, P , .05). Infants receiving INO had an adjusted baseline of 5.7 days of therapy, increasing by a little more than 1 day of therapy per treated infant each year during the study period (coefficient 1.04, 95% CI 1.01-1.07, P , .01). Rate of ECMO use (23% overall, hospital range 0%-52%), days of ECMO therapy per treated infant, and rate of CDH repair did not change significantly over the study period.
Mortality rates ranged from 14% to 65% between PHIS hospitals during the study period. Hospital-specific mortality rates for infants with CDH for the 9-year study period had a strong negative correlation with hospital-specific rates of CDH repair (r s = -0.79) (Fig 3) . However, hospital-specific rates Outcomes in addition to ECMO use and survival might be pertinent in considering whether INO treatment in newborns with CDH is indicated. There is evidence that early INO for CDH may provide short-term improvements before ECMO cannulation. 14 The largest randomized controlled trial of early INO for CDH found that nearly half of infants treated with INO improved PaO 2 by $10 Torr, a significantly better response rate than controls. 14 This improvement was not sufficient to reduce mortality or need for ECMO, and appears to be transient. 14, 21, 22 These studies suggest that early treatment with INO might provide short-term improvement in oxygenation in patients with CDH and severe pulmonary hypertension, and buy neonatologists and pediatric surgeons valuable time in the "bridge" period immediately before ECMO cannulation. However, the safety and efficacy of prolonged INO therapy in patients with CDH has not been thoroughly investigated in studies published to date. Small, open-label studies suggest that there may be a role for a safe, efficacious, and cost-effective pulmonary vasodilators for the treatment of significant postrepair pulmonary hypertension. INO significantly improved PaO 2 in cases of postrepair pulmonary hypertension, including in some infants who were nonresponders before repair, in an open-label crossover study. 23 Kinsella et al 24 27 Our results demonstrate that INO charges represent 12% of total hospital charges for patients with CDH, and shows that INO charges are greater than the combined charges for all the other drugs used to treat these patients.
Given the difficulty and cost of organizing randomized controlled trials for 
FIGURE 3
Relationship between mortality and rate of CDH repair (A), mortality and nitric oxide use (B), and ECMO use and nitric oxide use (C) among infants with CDH at 33 PHIS hospitals, 2003 to 2011.
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CDH, multicenter quality improvement collaboration may be a feasible alternative approach for improving CDH outcomes and reducing INO use. [28] [29] [30] This type of study would require active collaboration between participating centers committed to a common quality improvement protocol, and would need to be data driven with the objective of identifying effective therapies and emphasizing the clinical application of evidence-based interventions. [28] [29] [30] The infrastructure for such an effort already exists in the Congenital Diaphragmatic Hernia Study Group, a voluntary collaboration of international tertiary referral centers that provide data regarding patients with CDH to a central registry. 31 The Congenital Diaphragmatic Hernia Study Group data have yielded numerous high-quality observational studies addressing a variety of important issues in CDH management. [32] [33] [34] [35] Overall survival (66%), repair (80%), and ECMO utilization (23%) rates in this study are consistent with other reports of contemporary, multiinstitutional data regarding patients with CDH. 36 
